TNSN04138A1 - Metabolites de l'acide (3-{[4-tertiobutylbenzyl)-(pyridine-3-sulfonyl)-amino] - methyl}-phenoxy)-acetique - Google Patents

Metabolites de l'acide (3-{[4-tertiobutylbenzyl)-(pyridine-3-sulfonyl)-amino] - methyl}-phenoxy)-acetique

Info

Publication number
TNSN04138A1
TNSN04138A1 TNP2004000138A TNSN04138A TNSN04138A1 TN SN04138 A1 TNSN04138 A1 TN SN04138A1 TN P2004000138 A TNP2004000138 A TN P2004000138A TN SN04138 A TNSN04138 A TN SN04138A TN SN04138 A1 TNSN04138 A1 TN SN04138A1
Authority
TN
Tunisia
Prior art keywords
sulfonyl
phenoxy
pyridine
amino
methyl
Prior art date
Application number
TNP2004000138A
Other languages
English (en)
Inventor
Kimberly O'keefe Cameron
Kim Anne Johnson
Lefker Bruce Allen -
Chandra Aggarwal Prakash
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of TNSN04138A1 publication Critical patent/TNSN04138A1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/70Sulfur atoms
    • C07D213/71Sulfur atoms to which a second hetero atom is attached

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne des métabolites d'acide (3-{[4-tertiobutylbenzyl)-(pyridine-3-sulfonyl)-amino]-méthyl}-phénoxy)-acétique.
TNP2004000138A 2002-01-31 2004-07-27 Metabolites de l'acide (3-{[4-tertiobutylbenzyl)-(pyridine-3-sulfonyl)-amino] - methyl}-phenoxy)-acetique TNSN04138A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35374802P 2002-01-31 2002-01-31
PCT/IB2003/000121 WO2003064391A1 (fr) 2002-01-31 2003-01-20 Metabolites d'acide (3-{[4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetique

Publications (1)

Publication Number Publication Date
TNSN04138A1 true TNSN04138A1 (fr) 2007-03-12

Family

ID=27663249

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2004000138A TNSN04138A1 (fr) 2002-01-31 2004-07-27 Metabolites de l'acide (3-{[4-tertiobutylbenzyl)-(pyridine-3-sulfonyl)-amino] - methyl}-phenoxy)-acetique

Country Status (29)

Country Link
US (1) US6852863B2 (fr)
EP (1) EP1470109A1 (fr)
JP (1) JP2005521668A (fr)
KR (1) KR20040077884A (fr)
CN (1) CN1625549A (fr)
AP (1) AP2004003094A0 (fr)
AR (1) AR038332A1 (fr)
BR (1) BR0307339A (fr)
CA (1) CA2473984A1 (fr)
EA (1) EA200400724A1 (fr)
EC (1) ECSP045215A (fr)
GB (1) GB2400100B (fr)
HN (1) HN2003000051A (fr)
HR (1) HRP20040683A2 (fr)
HU (1) HUP0500012A2 (fr)
IL (1) IL162167A0 (fr)
IS (1) IS7281A (fr)
MA (1) MA27169A1 (fr)
MX (1) MXPA04004960A (fr)
NO (1) NO20043569D0 (fr)
OA (1) OA12760A (fr)
PA (1) PA8564601A1 (fr)
PE (1) PE20030978A1 (fr)
PL (1) PL371982A1 (fr)
TN (1) TNSN04138A1 (fr)
TW (1) TW200302080A (fr)
UY (1) UY27632A1 (fr)
WO (1) WO2003064391A1 (fr)
ZA (1) ZA200404067B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA67754C2 (uk) * 1997-10-10 2004-07-15 Пфайзер, Інк. Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти)
TWI332937B (en) * 2005-04-20 2010-11-11 Lg Chemical Ltd Additive for non-aqueous electrolyte and secondary battery using the same
JP4583500B2 (ja) * 2006-07-28 2010-11-17 ファイザー・プロダクツ・インク Ep2作動薬
WO2008112164A2 (fr) 2007-03-08 2008-09-18 The Board Of Trustees Of The Leland Stanford Junior University Modulateurs de l'aldéhyde déshydrogénase-2 mitochondrial, et leurs procédés d'utilisation
EP2002834A1 (fr) * 2007-06-13 2008-12-17 Bayer Schering Pharma Aktiengesellschaft Aryle/hétarylamides en tant que modulateurs du récepteur EP2
DK2264009T3 (en) * 2008-03-12 2019-04-15 Ube Industries PYRIDYLAMINE ACEDIC ACID COMPOUND
EP2149551A1 (fr) 2008-07-30 2010-02-03 Bayer Schering Pharma AG Dérivés de N-(indol-3-ylalkyl)-(hétéro)arylamide en tant que modulateurs du récepteur EP2
EP2149552A1 (fr) 2008-07-30 2010-02-03 Bayer Schering Pharma AG Dérivés de benzamide 5,6 substitués en tant que modulateurs du récepteur EP2
EP2149554A1 (fr) 2008-07-30 2010-02-03 Bayer Schering Pharma Aktiengesellschaft Indolylamides en tant que modulateurs du récepteur EP2
JP2012502048A (ja) 2008-09-08 2012-01-26 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ アルデヒドデヒドロゲナーゼ活性のモジュレーターおよびその使用方法
KR20110082180A (ko) 2008-10-28 2011-07-18 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 알데히드 탈수소효소의 조절자 및 그것의 사용방법
SI2415763T1 (sl) 2009-03-30 2016-05-31 Ube Industries, Ltd. Farmacevtski sestavek za zdravljenje ali preprečevanje glavkoma
DE102009049662A1 (de) 2009-10-13 2011-04-14 Bayer Schering Pharma Aktiengesellschaft 2,5-Disubstituierte 2H-Indazole als EP2-Rezeptor-Antagonisten
WO2012149106A1 (fr) 2011-04-29 2012-11-01 The Board Of Trustees Of The Leland Stanford Junior University Compositions et procédés d'augmentation de la prolifération de cellules souches salivaires adultes
TW201326154A (zh) 2011-11-28 2013-07-01 拜耳知識產權公司 作為ep2受體拮抗劑之新穎2h-吲唑
JP6410790B2 (ja) 2013-03-14 2018-10-24 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー ミトコンドリアアルデヒドデヒドロゲナーゼ−2調節因子およびその使用方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA67754C2 (uk) 1997-10-10 2004-07-15 Пфайзер, Інк. Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти)

Also Published As

Publication number Publication date
HUP0500012A2 (hu) 2005-04-28
GB0413967D0 (en) 2004-07-28
CN1625549A (zh) 2005-06-08
US6852863B2 (en) 2005-02-08
OA12760A (en) 2006-07-04
KR20040077884A (ko) 2004-09-07
WO2003064391A1 (fr) 2003-08-07
ZA200404067B (en) 2005-08-29
GB2400100A (en) 2004-10-06
AP2004003094A0 (en) 2004-09-30
MXPA04004960A (es) 2005-04-08
JP2005521668A (ja) 2005-07-21
BR0307339A (pt) 2004-12-07
PA8564601A1 (es) 2003-09-05
IL162167A0 (en) 2005-11-20
HN2003000051A (es) 2003-09-24
US20030216445A1 (en) 2003-11-20
IS7281A (is) 2004-05-21
CA2473984A1 (fr) 2003-08-07
ECSP045215A (es) 2004-09-28
TW200302080A (en) 2003-08-01
GB2400100B (en) 2006-04-12
NO20043569L (no) 2004-08-26
AR038332A1 (es) 2005-01-12
EA200400724A1 (ru) 2004-12-30
NO20043569D0 (no) 2004-08-26
PL371982A1 (en) 2005-07-11
EP1470109A1 (fr) 2004-10-27
PE20030978A1 (es) 2003-11-19
HRP20040683A2 (en) 2004-10-31
UY27632A1 (es) 2003-08-29
MA27169A1 (fr) 2005-01-03

Similar Documents

Publication Publication Date Title
TNSN04138A1 (fr) Metabolites de l'acide (3-{[4-tertiobutylbenzyl)-(pyridine-3-sulfonyl)-amino] - methyl}-phenoxy)-acetique
EA200500017A1 (ru) Новые соединения
CY1106247T1 (el) Θειοφαινο- και θειαζολοσουλφοναμιδες ως αντινεοπλαστικοι παραγοντες
MA29369B1 (fr) Dosage fixe d'anticorps anti-her
NO20041493L (no) Kjemiske forbindelser.
CY1107400T1 (el) Συνταγοποιηση κοκκου μοντελουκαστης
EA199900373A2 (ru) Фармацевтические композиции
DK1193270T3 (da) Pyrrolobenzodiazepiner
DK2014304T3 (da) Kolonrensende sammensætninger
CY1108567T1 (el) Αντιθρομβωτικες ενωσεις
BRPI0414593A (pt) derivados de ácido sulfonamida substituìda-indol-2-carboxìlico como inibidores de pai-1
SE0203713D0 (sv) Novel compounds
BR0014651A (pt) Inibidores de adesão de célula mediada por "alfa" l beta2
NO20042534L (no) Forbedringer vedrorende optiske lysgjoringsmidler
PE20011085A1 (es) Compuestos isoxazolquinolin o imidazolquinolin como inhibidores de la proteina resistente a multifarmacos
ATE438398T1 (de) Pyrrolo-dihydroisochinolin-derivate als pde10- inhibitoren
SE9901077D0 (sv) Novel use
ATE285753T1 (de) Lysin enthaltende kautablette
BR0008112A (pt) Agonistas de 5-ht 1f
SV2003000981A (es) Fenil-heterociclil-eteres ref. pcs10973
DE60332432D1 (de) Ibuprofen-lösung für hartschalenkapseln
BR0307978A (pt) Composição alvejante
DE60124717D1 (de) Aryl-sulfonamide als serotonin-antagonisten für de behandlung von fettleibigkeit
PT1206452E (pt) Processo de preparacao de compostos benzoper-hidroisoindole
AR027349A1 (es) Derivados de amidas heterociclicas